Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00150059|
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : February 15, 2008
To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication (treatment of patients > 3 months of age with mild to moderate atopic dermatitis)
This study is not enrolling patients in the United States.
|Condition or disease||Intervention/treatment||Phase|
|Atopic Dermatitis||Drug: Pimecrolimus Cream 1%||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||December 2004|
|Actual Study Completion Date :||December 2005|
- Drug: Pimecrolimus Cream 1%
Other Name: Elidel
- Investigator Global Assessment (IGA) score for the whole body and for the face only.
- Pruritus (itch) severity assessments, and patient's self-assessment of disease control at the start of study and on day 7, 30 and 90 after treatment initiation.
- Safety assessed by adverse events.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00150059
|This study is not being conducted in the United States|
|Investigative Site, Philippines|
|Study Chair:||Novartis Healthcare Philippines||Novartis Pharmaceuticals|